The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trialNadine Rouphael, Wendy Nesheim, Michele Paine et al.|The Lancet|2017Cited by 423
Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living FacilitiesMyron S. Cohen, Jason Morris, Elizabeth R. Brown et al.|JAMA|2021Cited by 208
Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120Nina D. Russell, Lawrence Corey, Barney S. Graham et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2006Cited by 104
Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like ParticlesPaul Goepfert, Harriet L. Robinson, Marnie Elizaga et al.|The Journal of Infectious Diseases|2014Cited by 84
Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescentsJianming Tang, Richard A. Kaslow, Craig M. Wilson et al.|AIDS|2002Cited by 63